There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-13


Brief Information

Target Synonym:Interleukin-13,IL13,Interleukin 13,IL-13,Bronchial Hyperresponsiveness-1 (Bronchial Asthma),Allergic Rhinitis,P600,NC30,MGC116789,MGC116788,BHR1,MGC116786,ALRH
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

IL3-H52H4-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human IL-13, His Tag (Cat. No. IL3-H52H4) stimulates proliferation of TF-1 cells. The EC50 for this effect is 0.05-0.08 μg/mL (Routinely tested).


Loaded Biotinylated Human IL-13, His,Avitag (Cat. No. IL3-H82E5) on SA Biosensor, can bind Human IL-13 R alpha 2, His Tag (Cat. No. IL2-H52H5) with an affinity constant of 6.31 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).


Loaded Human IL-13, Fc Tag (Cat. No. IL3-H5256) on Protein A Biosensor, can bind Human IL-13 R alpha 2, His Tag (Cat. No. IL2-H52H5) with an affinity constant of 6.09 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name



Interleukin 13 (IL13) is also known as ALRH, BHR1and P600, is a single-chain glycosylated polypeptide, and is a cytokine critical in regulating inflammatory and immune responses. IL13 is secreted by many cell types, but especially by T helper type 2 (Th2) cells. IL-13 induces its effects through a multi-subunit receptor that includes the alpha chain of the IL-4 receptor (IL-4Rα) and at least one of two known IL-13-specific binding chains. The functions of IL-13 overlap considerably with those of IL-4, especially with regard to changes induced on hematopoietic cells, but these effects are probably less important given the more potent role of IL-4. IL-13 induces matrix metalloproteinases (MMPs) as part of a mechanism that protects against excessive allergic inflammation that predisposes to asphyxiation. IL-13 induces many features of allergic lung disease, including airway hyperresponsiveness, goblet cell metaplasia and mucus hypersecretion, which all contribute to airway obstruction.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tralokinumab BAK-502G9; CAT-354 Approved Medimmune Llc Adtralza EU Dermatitis, Atopic Leo Pharma A/S 2021-06-17 Idiopathic Pulmonary Fibrosis; Colitis, Ulcerative; Asthma; Dermatitis, Atopic Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Dectrekumab/VAK-694 QBX-258 Phase 2 Clinical Novartis Pharma Ag Lymphedema; Asthma Details
Cendakimab ABT-308; RPC-4046 Phase 2 Clinical Abbott Laoratories Eosinophilic Esophagitis; Asthma Details
Romilkimab SUB-33159; SAR-156597 Phase 2 Clinical Sanofi Idiopathic Pulmonary Fibrosis; Scleroderma, Systemic Details
Lebrikizumab RG-3637; TNX-650; Anti-IL-13; MILR-1444A; PRO-301444; RO-4909832; RO-5490255; DRM-06; R-3637 Phase 3 Clinical Genentech Inc Hodgkin Disease; Idiopathic Pulmonary Fibrosis; Dermatitis; Skin Diseases; Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic; Eczema; Skin Diseases, Genetic Details
LQ-036 LQ-036 Phase 1 Clinical Shanghai Novamab Biopharmaceuticals Co Ltd Asthma Details

This web search service is supported by Google Inc.